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The Step 2 Clinical Skills Exam
To the Editor: We agree with the Perspective 
article by Lehman and Guercio (March 7 issue)1 
that national clinical exams are expensive. We 
also agree with First et al.2 that such exams pos-
itively shape the educational and assessment pro-
grams of medical schools, promote standardi-
zation of accreditation criteria, and provide an 
essential service to the public by filtering out 
candidates in need of remediation of deficient 
skills. We feel, however, that a crucial aspect has 
been ignored so far: the effect of the exam on all 
students taking it. The role of summative assess-
ment in shaping student learning is being de-
fined in a growing body of literature.3-5 We may 
ignore to our peril the implied warning that 
without a mandatory high-stakes clinical skills 
exam, too many new graduates may lack the clin-
ical skills deemed critical to effective health care. 
Considering its positive effects, a national clini-
cal skills exam seems an excellent value proposi-
tion indeed.
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To the Editor: Lehman and Guercio conclude 
that the U.S. Medical Licensing Examination 
(USMLE) Step 2 Clinical Skills (CS) exam pro-
duces a poor return on investment. Their compu-
tation is based on the explicit costs of the exam 
to students. They evaluate the benefits only in 
terms of screening out unqualified applicants. 
Lehman and Guercio do not consider that requir-
ing passage of Step 2 CS has also compelled 
medical schools to bolster clinical-skills educa-
tion in their curricula.
Every exam should correspond to educational 
activities in which students learn the knowledge 
and skills needed to pass that exam.1 Delivering 
a preparatory curriculum for licensure exams is 
an ethical obligation for medical schools. A sub-
stantial benefit of Step 2 CS stems from curricu-
lar innovations that medical schools have made 
to prepare students for the exam. Contemporary 
curricula include instruction in fundamental 
clinical skills and inculcation of the importance 
of those skills.
An investment cannot be measured exclu-
sively by its cost, but rather, the cost must be 
balanced against the benefit realized from the 
expenditure. In this case, Lehman and Guercio 
discounted the value of the curriculum innova-
tions that occurred in response to the imposition 
of Step 2 CS.
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The Authors Reply: Huwendiek et al. argue that 
the USMLE Step 2 CS exam “filter[s] out candi-
dates in need of remediation.” As shown, be-
cause of the high pass rates, the exam annually 
filters out only 32 candidates who fail the exam 
twice. Since candidates may take the exam six 
times,1 Step 2 CS only delays — but does not 
filter out — the practice of medicine by any fu-
ture physician. Furthermore, we question the no-
tion that “without a mandatory high-stakes clin-
ical skills exam, too many new graduates may 
lack the clinical skills deemed critical to effective 
health care.” This statement incorrectly implies 
that passing a high-stakes clinical exam ensures 
a sufficient level of clinical skills. This belief is as 
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erroneous as the contrapositive of the argument, 
that physicians who have not passed a clinical 
skills exam lack a sufficient clinical skill set. The 
test was instituted in 2004, so this logic raises 
the question of whether hundreds of thousands 
of otherwise-licensed physicians are truly clini-
cally competent, given that they graduated with-
out taking Step 2 CS.
We agree with Stoddard that there may be 
benefits stemming from curriculum innovations 
designed “in response to the imposition of Step 2 
CS.” But this statement is telling: medical schools 
are teaching (and thus students are learning) for 
a test. The argument prompts the question of 
whether a costly, daylong exam — as opposed to 
Liaison Committee on Medical Education guide-
lines or regulations — is truly the best mecha-
nism for ensuring the clinical skills that all physi-
cians must have on graduating from medical 
school.
Our Perspective article did not claim to be an 
exhaustive cost–benefit analysis. It did, however, 
highlight a major cost borne directly by physi-
cians and question a nebulous benefit that nei-
ther the National Board of Medical Examiners 
nor the Federation of State Medical Boards has 
definitively quantified. Step 2 CS serves as little 
more than an expensive rubber stamp on top of a 
student’s medical education. We believe it should 
be eliminated, unless its benefits — like those 
of any other medical intervention — are conclu-
sively shown.
Elmer Philip Lehman IV, M.D., M.P.P. 
Jason Ross Guercio, M.D., M.B.A.
Duke University School of Medicine 
Durham, NC 
philip.lehman@duke.edu
Since publication of their article, the authors report no fur-
ther potential conflict of interest.
1. 2013 Bulletin of information. Philadelphia: United States 
Medical Licensing Examination (http://www.fsmb.org/pdf/
USMLEStep3_bulletin.pdf).
DOI: 10.1056/NEJMc1304496
JC Viremia in Natalizumab-Treated Patients  
with Multiple Sclerosis
To the Editor: We analyzed plasma samples for 
the presence of JC virus antibodies and viral 
DNA. The samples were obtained from separate 
cohorts of patients with multiple sclerosis who 
received monthly infusions of natalizumab. 
Blood samples were obtained from 26 patients 
immediately before the first infusion (the base-
line) and for several months during the first year 
of treatment. Blood samples also were obtained 
from 23 patients once after more than 24 months 
of treatment. Antibody titers and viral DNA1 
were measured by means of an enzyme-linked 
immunosorbent assay with the use of JC viruslike 
particles (the Biogen Stratify assay uses similar 
viruslike particles).2 We also used an ultrasensi-
tive quantitative polymerase-chain-reaction (PCR) 
assay specific for JC virus DNA.1 Our procedures 
were certified in accordance with the Clinical 
Laboratory Improvement Amendment. The Labo-
ratory of Molecular Medicine and Neuroscience 
has provided quantitative PCR results that have 
confirmed the diagnosis of progressive multifo-
cal leukoencephalopathy (PML) in approximately 
half the 370 cases of PML in natalizumab-treated 
patients with multiple sclerosis.
Overall, 17 of the 49 patients (35%) had vire-
mia at some time. Ten of 26 patients in whom 
treatment was initiated had viremia; 4 were sero-
negative (antibody titer, <2560) and 6 were sero-
positive (antibody titer, ≥2560).1 Of these patients, 
4 had viremia at baseline and 3 were seroposi-
tive. Seven of 23 patients who received more than 
24 infusions had viremia and 2 were seronega-
tive. One blood sample was obtained from each 
of the 18 healthy volunteers; 6 were seronega-
tive, 12 were seropositive, and none had detect-
able viral DNA.
Fisher’s exact test was used to determine a 
statistical difference between the treated patients 
who had viremia and healthy volunteers (P = 0.003) 
(Table 1). We observed a range in viral titers 
from 13 to 510 copies of JC virus DNA per milli-
liter (mean, 43 copies per milliliter) in patients 
in the initial year of treatment and from 21 to 
126 copies (mean, 40 copies per milliliter) in 
those who received more than 24 infusions. Of 
the 17 persons with viremia, 11 were seroposi-
tive (65%) and 6 were seronegative (35%).
Although viremia by itself is not a predictor 
of the risk of PML, the observation that viremia 
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